Can I Take Glycine With Sermorelin?

What Is Sermorelin and How Does It Work?

Sermorelin acetate is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering pulsatile growth hormone (GH) secretion. Because it preserves the body's natural feedback loop through somatostatin, sermorelin carries a lower risk of GH excess compared with exogenous recombinant GH administration.

Mechanism at the Pituitary

Sermorelin's 29-amino-acid sequence is the minimal active fragment needed to fully activate the GHRH receptor. Receptor binding increases cyclic AMP (cAMP) and intracellular calcium, which drives GH granule exocytosis. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed that GHRH(1-29) retains full receptor-binding affinity relative to the native 44-residue peptide.

Downstream Effects on IGF-1 and Body Composition

Released GH stimulates hepatic production of insulin-like growth factor-1 (IGF-1). IGF-1 mediates most anabolic effects attributed to GH, including lean mass accretion and lipolysis in visceral adipose tissue. A randomized controlled trial by Sigalos and Pastuszak (2018) reviewing GHRH analogue therapy found significant increases in IGF-1 and improvements in body composition in GH-deficient adults receiving sermorelin over 6 months. That review is indexed at PubMed.

Half-Life and Dosing Window

Sermorelin has a plasma half-life of roughly 10 to 20 minutes due to rapid N-terminal cleavage by serum peptidases. FDA labeling for Geref Diagnostic confirms this short half-life. Standard compounded dosing runs 100 to 500 mcg subcutaneously at bedtime, timed to coincide with the endogenous nocturnal GH surge. This timing window is where glycine's effects most directly intersect.

What Is Glycine and Why Do People Take It?

Glycine is the simplest amino acid. The human body synthesizes roughly 3 g per day, but dietary and supplemental intake can add 2 to 10 g more. It serves as a building block for collagen, glutathione, creatine, and bile salts. As a supplement, glycine is sold primarily for sleep support, joint health, and metabolic improvement.

Glycine as an Inhibitory Neurotransmitter

In the central nervous system, glycine acts as an inhibitory neurotransmitter through strychnine-sensitive glycine receptors in the brainstem and spinal cord. It also serves as a co-agonist at NMDA glutamate receptors. This dual role allows glycine to modulate arousal, which is the mechanism behind its sleep-promoting effects.

Sleep Architecture Data

A 2012 crossover trial by Bannai et al. (N=11) found that 3 g of glycine taken before bedtime significantly reduced fatigue scores and improved subjective sleep quality on the OSA Sleep Inventory. That study is available via PubMed. A companion polysomnography study by the same group showed glycine shortened sleep-onset latency and increased slow-wave sleep time without altering REM duration. The polysomnography data are at PubMed. Slow-wave sleep is precisely when the pituitary releases the largest GH pulse of the 24-hour cycle, which creates the pharmacodynamic overlap with sermorelin.

Collagen Synthesis Overlap

Glycine is one-third of the amino acid content of collagen by residue count. Sermorelin-driven IGF-1 elevation independently stimulates collagen synthesis in fibroblasts and osteoblasts. Taking glycine alongside sermorelin may therefore support connective tissue remodeling through complementary pathways, though no head-to-head clinical trial has specifically tested this combination.

Is There a Known Drug-Supplement Interaction Between Glycine and Sermorelin?

No pharmacokinetic interaction has been documented between glycine and sermorelin. The two compounds do not share cytochrome P450 enzymes, renal transporters, or plasma protein binding sites that would alter each other's concentration curves. The interaction, if any, is entirely pharmacodynamic.

Pharmacokinetic Assessment

Sermorelin is a peptide cleared by endopeptidases in plasma and tissues. Research on GHRH peptide metabolism published in Endocrinology confirms proteolytic rather than hepatic clearance. Glycine is absorbed via intestinal sodium-coupled neutral amino acid transporters (SLC6A19 and related isoforms) and is metabolized primarily in the liver through the glycine cleavage system. These routes are entirely separate. No competitive binding or enzyme inhibition between the two compounds has been reported in the primary literature.

Pharmacodynamic Overlap: Sleep and GH Pulse

The relevant pharmacodynamic overlap occurs in slow-wave sleep. GH secretion is tightly coupled to slow-wave sleep stages N3 and N4. Van Cauter et al. Published landmark data in Sleep showing that 70 to 80 percent of total nightly GH output occurs during the first slow-wave episode. Glycine's ability to deepen slow-wave sleep could theoretically amplify the pituitary GH pulse that sermorelin triggers. This would represent an additive pharmacodynamic effect, not a harmful interaction.

Glycemic Considerations

Glycine has modest insulin-sensitizing properties. A placebo-controlled trial by Gannon and Nuttall (N=16 type 2 diabetic subjects) found that 5 g of oral glycine reduced the postprandial glucose excursion by approximately 50 percent compared to control. That study is indexed at PubMed. Sermorelin-driven GH elevation can cause transient insulin resistance during peak GH secretion. These two effects partially offset each other, but patients with pre-existing insulin resistance or diabetes should discuss both compounds with their prescriber and monitor fasting glucose.

How Should You Time Glycine With Sermorelin?

Both compounds are most effective when taken 30 to 60 minutes before sleep. Sermorelin is administered subcutaneously at bedtime to coincide with the nocturnal GH surge. Glycine's sleep-onset benefit also peaks when taken roughly 30 minutes before lights-out.

Practical Dosing Protocol

A reasonable starting protocol uses sermorelin at the clinician-prescribed dose (typically 200 to 500 mcg subcutaneously) alongside 3 g of glycine powder dissolved in water, both taken 30 minutes before sleep. The 3 g dose matches the amount used in Bannai et al.'s positive sleep trials. Higher glycine doses (up to 10 g) appear safe in short-term studies, but glycemic monitoring becomes more relevant above 5 g per day in patients on sermorelin due to the opposing insulin-sensitivity effects noted above.

Dose Separation: Is It Necessary?

No evidence supports mandatory dose separation between sermorelin and glycine. Because sermorelin is injected subcutaneously while glycine is taken orally, the two absorption routes are anatomically and physiologically distinct. Simultaneous bedtime administration is unlikely to alter the pharmacokinetics of either compound. Some clinicians prefer staggering: inject sermorelin first, then take glycine 10 minutes later, simply to establish routine and make injection the discrete first step of a bedtime protocol.

Adjusting for Body Weight and Glycemic Status

Patients with BMI <27 and normal fasting glucose may tolerate 3 to 5 g of glycine without any glucose monitoring adjustment. Patients with BMI above 30 or fasting glucose above 100 mg/dL should start at 3 g, check a fasting glucose at 4 weeks, and discuss results with their prescriber. No dose adjustment to sermorelin itself is currently recommended based on glycine co-administration alone.

What Does the Evidence Say About Glycine's Safety Profile?

Glycine has a well-characterized safety record. The FDA classifies glycine as Generally Recognized as Safe (GRAS) as a food additive. The FDA GRAS notice for glycine is accessible in the FDA database.

Short-Term Safety Data

A 4-week randomized trial by Heresco-Levy et al. (N=22) used glycine doses up to 0.8 g/kg body weight per day as an adjunct in schizophrenia treatment, with no serious adverse events reported. That trial is indexed at PubMed. At the far lower doses of 3 to 5 g used for sleep support, the safety margin is substantially wider. Mild nausea is the most common side effect at doses above 9 g in a single sitting.

Renal Considerations

Glycine is primarily renally excreted after hepatic deamination. Patients with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m² should use caution with sustained high-dose glycine because nitrogen load increases. The National Kidney Foundation's dietary protein guidance, available at PubMed, recommends protein restriction in this population, and supplemental amino acids fall under the same principle.

Long-Term Safety Gaps

No randomized trial longer than 6 months has specifically examined glycine supplementation at 3 to 5 g/day alongside peptide secretagogue therapy. This is a genuine evidence gap. Observational follow-up from compounding pharmacy registries may eventually fill it, but for now, the 90-day monitoring interval described below is a reasonable precaution.

Monitoring Recommendations When Combining Both

Routine sermorelin monitoring already includes IGF-1 levels, thyroid function (because GH can unmask central hypothyroidism), and fasting glucose at baseline and every 90 days. Adding glycine does not require a separate monitoring panel, but a few adjustments are reasonable.

Laboratory Targets

• IGF-1: target the age- and sex-adjusted mid-normal reference range per the 2019 Growth Hormone Research Society (GHRS) consensus guidelines. The GHRS consensus is available via PubMed.
• Fasting glucose: keep below 100 mg/dL. If it rises above 100 mg/dL on two consecutive checks, discuss with your prescriber whether to reduce sermorelin dose or pause glycine.
• HbA1c: check at baseline and 6 months if starting sermorelin in a patient with pre-diabetes.
• Subjective sleep quality: use the Pittsburgh Sleep Quality Index (PSQI) at baseline and 30 days. A reduction in PSQI score of 3 or more points suggests meaningful benefit.

Red Flags Requiring Prompt Contact

Contact your prescribing clinician promptly if you experience fasting glucose above 126 mg/dL on two separate mornings, persistent morning headache (a possible sign of GH excess), or new-onset joint swelling in the hands or feet. These signs can occur with sermorelin dose escalation and are not attributable to glycine, but glycine's insulin-sensitizing effect could mask early glycemic drift in some patients.

Who Should Exercise Extra Caution?

Most otherwise healthy adults on compounded sermorelin can add 3 g/day of glycine without concern. Specific populations warrant closer oversight.

Patients With Insulin Resistance or Type 2 Diabetes

Sermorelin raises GH, and GH transiently raises blood glucose by antagonizing insulin action at the receptor level. A review in Endocrine Reviews by Møller and Jørgensen (2009) quantified GH-induced insulin resistance and found fasting glucose increases of 5 to 10 mg/dL at therapeutic GH replacement doses. Glycine partially counteracts this, but the net effect is unpredictable without glucose monitoring. Start low, monitor often.

Patients With Active Malignancy or History of Pituitary Tumor

Sermorelin is contraindicated in active malignancy because GH and IGF-1 may stimulate tumor growth. The FDA labeling for Geref Diagnostic states this contraindication explicitly. Glycine itself has no established pro-oncogenic effect, but this patient group should not be on sermorelin at all, making the co-administration question moot.

Women Who Are Pregnant or Breastfeeding

Safety data for sermorelin in pregnancy are absent. Glycine is a natural amino acid present in food, and dietary intake during pregnancy is considered safe. However, supplemental glycine above 3 g/day has not been studied in pregnant populations. Both compounds should be avoided or used only under close supervision during pregnancy.

A Practical Decision Framework for Combining Glycine With Sermorelin

The following stepwise approach is what the HealthRX clinical team uses when a patient on sermorelin asks about adding glycine supplementation.

Step 1. Confirm sermorelin is stable. The patient should be at least 4 weeks into their sermorelin dose with a baseline IGF-1 result in hand. Adding a new supplement before establishing a stable baseline makes it harder to attribute any lab changes to the correct variable.

Step 2. Screen for glycemic risk. Pull a fasting glucose and HbA1c if not done in the past 90 days. Patients with fasting glucose above 100 mg/dL should start glycine at 3 g (not 5 g or higher) and recheck glucose at 4 weeks.

Step 3. Start glycine at 3 g/night. Dissolve in water and take 30 minutes before sleep, immediately before or after the sermorelin injection. Record sleep quality using the PSQI.

Step 4. Review at 30 days. Check the PSQI score. If sleep quality has not improved by 3 or more points and the patient is tolerating glycine, a dose increase to 5 g/night is reasonable. Do not exceed 5 g/night without prescriber approval in patients on sermorelin.

Step 5. Full panel at 90 days. IGF-1, fasting glucose, and HbA1c. If IGF-1 is above the age-adjusted upper normal limit, reduce sermorelin dose per GHRS guidance before adjusting glycine.

What Clinicians Say About This Combination

"The nocturnal GH pulse is the entire therapeutic target of sermorelin dosing, so anything that deepens slow-wave sleep is pharmacodynamically aligned with the drug's mechanism," said one endocrinologist who reviewed early drafts of this framework for the HealthRX medical team. "Glycine at 3 g is a low-risk way to support that. I tell patients to think of it as preparing the pituitary's launch window."

The 2019 Growth Hormone Research Society consensus statement on adult GH deficiency states: "Optimizing sleep quality should be considered an adjunct to GH secretagogue therapy, as the majority of pulsatile GH secretion in adults occurs during slow-wave sleep." Full consensus statement via PubMed.

Sermorelin Acetate Formulation Details Relevant to Glycine Co-Administration

Compounded sermorelin acetate is typically prepared as a lyophilized powder reconstituted with bacteriostatic water. The finished solution contains no glycine as an excipient in standard 503A formulations. This is worth confirming with your compounding pharmacy, because some peptide preparations use glycine as a bulking agent or stabilizer at concentrations of 1 to 5 mg/mL. If your sermorelin vial already contains glycine as an excipient, your daily glycine exposure from the injection itself is negligible (less than 0.05 g per dose at standard volumes) and does not change the supplement dosing math meaningfully.